Boeing Expert Says 737 MAX Freeze & Certification Challenges May Lead To Customer Loss: BofA Analyst
BofA Analyst discusses with Chris Brady about FAA's production freeze of Boeing's 737 MAX and potential implications for certification.
Axsome Depression Drug’s Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.
Nikola To Gain From State Or Federal Incentive Programs In New Geographies, Analyst Sees New CFO Under CEO Steve Girsky
Nikola receives an Outperform rating from Baird analyst, citing significant potential in the zero-emissions trucking market, proprietary design and software advantages, and anticipates positive catalysts in manufacturing, customer announcements, and hydrogen infrastructure developments.
Intel Q4 Earnings Preview: Analysts Cautious For 2024, Envisions ‘More-Clouded Picture’ After Strong 2023
Intel Corp (INTC) to report Q4 earnings on Jan. 25, with expected revenue of $15.16B. Stock up 61.51% in past year, but faces risks in 2024.
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: ‘Innovation Is Key’
Innovation and digitalization have been in focus among ophthalmology majors.
Rocket Lab Has A Proven Business Model and Viable Profitability Path In 1-3 Years: Keybanc Analyst
Keybanc Analyst Bullish on Rocket Lab: Michael Leshock initiates coverage on RKLB with an Overweight rating, setting a $8 price target. Leshock highlights RKLB's proven business model and viability for profitability within 1-3 years, amidst rising demand for launch services and satellite manufacturing.
Aramark At An Inflection Point For Pricing Growth – Goldman Sachs Is Bullish
Goldman Sachs analyst Lizzie Dove gives Aramark a Buy rating with a $33 target, predicting an upcoming pricing growth inflection. Dove notes that ARMK's significant growth in net new business and shifts towards outsourcing post-COVID signal strong revenue potential.
Cholesterol Player NewAmsterdam Pharma’s Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says
Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and market potential, Piper gives an Overweight rating and a $37 price target.
NEXTracker Sparks Goldman Analyst’s Optimism Thanks To Tax Credits
Goldman Sachs analyst Brian Lee initiated coverage on NEXTracker Inc at a Buy rating with a price target of $62.